209 related articles for article (PubMed ID: 22057854)
1. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD
Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854
[TBL] [Abstract][Full Text] [Related]
2. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
[TBL] [Abstract][Full Text] [Related]
3. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD; Hong WK
J Clin Oncol; 2001 May; 19(10):2626-37. PubMed ID: 11352954
[TBL] [Abstract][Full Text] [Related]
7. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma.
Chen YM; Yu CJ; Yang CH; Perng RP; Tsai CM; Shih JF; Cheng AL; Lefresne F; Barbier M; Pouget JC; Yang PC
Lung Cancer; 2007 Apr; 56(1):89-95. PubMed ID: 17208330
[TBL] [Abstract][Full Text] [Related]
9. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC.
Pallis AG; Chandrinos V; Pavlakou G; Xenidis N; Varthalitis I; Vardakis N; Vamvakas L; Kontopodis E; Rovithi M; Georgoulias V
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1239-45. PubMed ID: 20697712
[TBL] [Abstract][Full Text] [Related]
14. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
15. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?
Provencio M; de Las Peñas R; Camps C; Artal A; Massuti B; Cobo M; Pérez FJ; Sánchez A; Rosell R
Lung Cancer; 2010 Jun; 68(3):415-9. PubMed ID: 19695734
[TBL] [Abstract][Full Text] [Related]
18. A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.
Tibaldi C; Baldini E; Ricci S; Conte PF
Anticancer Res; 1996; 16(5B):3213-5. PubMed ID: 8920792
[TBL] [Abstract][Full Text] [Related]
19. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
Cigolari S; Curcio C; Maiorino A; Sessa R; Cioffi A; Massimo M
Anticancer Res; 2003; 23(2C):1803-9. PubMed ID: 12820462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]